Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
CERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $2.54
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.45M
Market Cap
$289.83M
Enterprise Value$345.76M
Total Cash (Recent Filing)$20.27M
Total Debt (Recent Filing)$33.23M
Price to Earnings (P/E)―
Beta3.02
Next Earnings
May 01, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding185,789,810
10 Day Avg. Volume1,793,888
30 Day Avg. Volume1,447,281
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.58
Price to Cash Flow (P/CF)14.40
P/FCF Ratio18.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.47
Enterprise Value/Ebitda-34.49
Forecast
1Y Price Target
$4.00Price Target Upside156.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Cerus News
PremiumCompany Announcements
Cerus Corporation’s 2024 Earnings Call Highlights Growth and Expansion
PremiumCompany Announcements
Cerus Corporation Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Cerus Director Gail Schulze to Step Down---
Bulls Say, Bears Say
Bulls Say
Financial GuidanceManagement raised its full-year guidance due to strong momentum from the launch of IFC.
Product LaunchThe commercial launch of the new IFC offering is off to a strong start, with IFC sales set to be a key part of the company's growth in 2025.
Product RevenueCerus Corporation reported a Q4 top line beat and drove 15% year-over-year product revenue growth in 2024, surpassing its initial guidance.
Bears Say
Regulatory ApprovalThe CE mark review for INTERCEPT RBCs in Europe concluded without an approval, marking a disappointing setback for the company.
Regulatory StrategyThe review of CERS's CE Mark application for INTERCEPT RBC was completed without receiving approval, prompting the company to assess new strategies for regulatory submission.
ValuationShares of CERS trade below small cap peers on an EV/sales basis, suggesting the stock is roughly fairly valued.
---
Ownership Overview
15.94% Insiders
16.04% Mutual Funds
42.44% Other Institutional Investors
4.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CERS FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was $1.38 and its highest was $2.54 in the past 12 months.
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is $289.83M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is May 01, 2025 which is in 36 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Feb 20, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.002.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is -0.04.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 185,789,810 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went down -5.172%.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CERS
---
Cerus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (156.41% Upside)
$4.00 (156.41% Upside)
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.53%
12-Months-Change
Fundamentals
Return on Equity
-38.45%
Trailing 12-Months
Asset Growth
1.60%
Trailing 12-Months
Company Description
Cerus Corp
Cerus Corporation is a biomedical products company engaged in the development and commercialization of the INTERCEPT Blood System, a proprietary blood safety technology. The company operates primarily within the biotechnology and healthcare sectors, focusing on enhancing the safety of blood transfusions. Cerus's core products include systems designed to inactivate pathogens in platelets and plasma, which are critical components used in blood transfusions.
---
CERS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Cerus Corporation's strong financial performance in 2024, marked by positive adjusted EBITDA and robust revenue growth driven by the IFC and global platelet businesses. However, challenges such as a decline in government contract revenue and increased operating expenses were noted. The overall sentiment is positive given the company's growth trajectory and market expansion efforts.Read More>---
CERS Stock 12 Month Forecast
Average Price Target
$4.00
▲(156.41% Upside)
Technical Analysis
Fate Therapeutics
―
Heron Therapeutics
―
CytomX Therapeutics
―
Anixa Biosciences
―
Allogene Therapeutics
―
Best Analysts Covering CERS
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-10.47%
reiterated a buy rating last month
Copying Josh Jennings's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -10.47% per trade.
---